source
- FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic CancerThe U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanc…fda press · 2h ago↗ source
- Ambros Therapeutics merges with Werewolf, raises $150M to fund phase 3 trial of rare disease drugAmbros Therapeutics announced an all‑stock reverse merger with Werewolf Therapeutics, accompanied by a $150 million private placement. The transaction will see the combined company operate under th…